单用表阿霉素缓释剂及联合表阿霉素游离剂腹腔化疗治疗肝癌的疗效

目的观察单用表阿霉素(EPI)聚乳酸(PLA)缓释微球(MS)及联合游离表阿霉素(FEPI)腹腔化疗治疗肝癌的疗效。方法将35只H22腹水型肝癌荷瘤小鼠分为7组,每组5只,分别予空白微球,生理盐水,低、中、高剂量载药微球(分别含EPI 9、18、36 mg/kg),FEPI(9 mg/kg)和EPI-PLA-MS+FEPI(各含EPI 4.5 mg/kg),经腹腔注射给药,计算动物生命延长率。结果EPI-PLA-MS能有效延长荷瘤鼠的生存时间,并呈量效关系,小鼠最大耐受量约为18~36 mg/kg。联合用药组的平均生存时间、中位生存时间和生命延长率均达到最高值,分别为(40.0±16.9)d、33.5 d和222.58%。结论EPI-PLA-MS缓释剂与游离剂型联合腹腔化疗是一种新型、高效的给药方式,可有效治疗肝癌

Treatment of Hepatocellular Carcinoma in Mice with Locally Administered Epirubicin-loaded Poly(D,L)-lactic Acid Microspheres

[中文文摘]目的研究表柔比星-聚乳酸缓释微球(EPI-PLA-MS)局部给药治疗肝癌的效果。方法复乳-溶剂挥发法制备EPI-PLA-MS。将40只昆明小鼠随机分为5组,每组8只,分别腹腔注射不同剂量的游离表柔比星(FEPI),计算最大耐受量(MTD)。H22皮下实体瘤肝癌荷瘤小鼠3组,每组5只,分别用生理盐水(normalsaline,NS)、空白微球和含药微球(含EPI9mg/kg)瘤内注射给药,2周后取瘤称重。H22腹水型肝癌荷瘤小鼠3组,每组5只,分别用NS、空白微球和含药微球(含EPI9mg/kg)腹腔注射给药,计算动物生命延长率。结果FEPI腹腔注射的MTD为9mg/kg。EPI-PLA-MS瘤内给药后含药微球组和空白微球组的抑瘤率分别为40.35%和36.09%。腹腔给药后能显著延长荷瘤鼠的生存时间,含药微球组和空白微球组生命延长率分别为153.49%和142.22%。结论EPI-PLA-MS是一种有效低毒的药物新剂型,在局部治疗肝癌方面具有良好的临床应用前景。[英文文摘]Objective To study the effectiveness of treating hepatocellular carcinoma(HCC)in mice with locally administered epirubicin-loaded poly(D,L)-lactic acid microspheres(EPI-PLA-MS).Methods EPI-PLA-MS was prepared with double emulsion solvent evaporation technique.Five groups of mice(n=8 in each group)were intraperitoneally injected with five different doses of free epirubicin(FEPI),and the maximum tolerated dose(MTD)was calculated.Then 15 mice with transplanted subcutaneous H 22 HCC were divided into three group s ( n = 5) , which were respectively intratumorally injected with normal saline (NS) , blank micro-spheres, and EPI-PLA-MS (with 9mg/kg of EPI) 1 After two weeks the tumorswere excised and weighed1 Another 15 mice with transp lanted H22 ascites HCC were divided into three groups (n=5) , which were intraperitonealy injected with the same drugs, and the increased life span were registered exactly1 Resutls　TheMTD of intraperito neally injected FEPIwas 9mg/kg1 The tumour inhibiting rateswas 40135% and 36109% when EPI-PLA-MS were administered by intratumoral injection to the mice with subcutaneous H22 HCC1 It significantly p rolonged the survival time of mice with H22 ascites HCC and the increased life span by 153149% and 142122% when EPI-PLA-MS were intraperitoneally administered1 Conclusion　EPI-PLA-MS is a new sustained release preparation with high-ef-ficacy and low-toxicity in treating HCC and has shown promising prospects when administerd locally

Analysis of recombinant human endostatin injection off label use in 120 inpatients in our hospital

目的:分析某院住院患者恩度用药医嘱的合理性,促进临床合理用药。方法:收集2016年1月-2016年12月期间出院的住院患者的恩度用药医嘱,将患者诊断、用法用量与恩度药品说明书进行对比分析,统计超药品说明书情况。结果:120例使用恩度的患者中,男性多于女性,超说明书适应证医嘱24条,占20.00%,超说明书用法用量医嘱117条,占97.50%;有1例发生不良反应,表现为发热。结论:恩度超药品说明书较为普遍,需要设计合理、大样本的随机对照双盲研究提供依据支持